Akouos is building the leading gene therapy company focused on hearing disorders. Our objectives are to restore the inner ear’s ability to produce functional proteins required for hearing, rejuvenate structures of the hearing circuit critical for high-fidelity signal transduction and inner ear homeostasis, and reinforce healthy hearing with local, enduring protein production to protect against drug-, noise-, and age- associated ototoxicity.
Ensuring delivery to the right cells, in the right amounts, and at the right time is central to our ability to restore and preserve hearing. Recombinant adeno-associated viruses (AAVs) can be harnessed as powerful vectors that are capable of safely and efficiently delivering therapeutic nucleic acids to the nuclei of target cells. Akouos’ initial focus is on delivery of AAV gene therapies to treat hearing loss in genetically-defined patient populations.
Akouos launched in 2017 with backing from 5AM Ventures, New Enterprise Associates, and Partners Innovation Fund.